论文部分内容阅读
血小板合成的血栓素 A_2(Thromboxane A_2,TXA_2)具有较强的血小板聚集作用和缩血管作用,而血管内皮合成的前列腺素 I_2(Prostaglan-dinI_2,PGI_2,又叫前列环素 Prostacyclin)却具有相反的作用,即可抑制血小板聚集并使血管舒张。正常情况下两者处于动态平衡状态,从而有助于维持血液及血管的稳态。如果这种平衡失调,例如,TXA_2合成过量或 PGI_2合成不足,均可能导致血栓形成及血栓栓塞性疾病的发生。根据这一理论,目前国外已提出如下抗血栓形成治疗措施。一、使用环加氧酶抑制阿斯匹林通过抑制血小板环加氧酶而可抑制TXA_2的合成,从而可抑制其聚集和延长出血时
Platelet-derived thromboxane A 2 (TXA 2) has strong platelet aggregation and vasoconstriction, whereas prostaglandin I 2 (PGI 2, also known as prostacyclin) synthesized by the vascular endothelium has the opposite Role, you can inhibit platelet aggregation and vasodilation. Under normal circumstances the two are in a state of dynamic equilibrium, which helps to maintain blood and blood vessel homeostasis. If this imbalance, for example, TXA_2 over-synthesis or PGI_2 under-synthesis, may lead to thrombosis and thromboembolic disease. According to this theory, at present, the following anti-thrombosis treatment measures have been proposed abroad. First, the use of cyclooxygenase inhibition Aspirin inhibition of platelet cyclooxygenase and can inhibit TXA_2 synthesis, which can inhibit the aggregation and prolong bleeding